Ponatinib Hydrochloride 10 mg, 15 mg, 30 mg, 45 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg, 15 mg, 30 mg, 45 mg

Reference Brands: Iclusig (USA)

Category: Oncology Cancer Care

Ponatinib is a third-generation tyrosine kinase inhibitor that targets BCR‑ABL, including the T315I mutation, which is resistant to earlier TKIs. It is used primarily to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia

Product Description:

Ponatinib is a third-generation BCR-ABL inhibitor designed around a single obstacle. The T315I mutation replaces a small threonine in the kinase pocket with a bulky isoleucine, and every earlier inhibitor simply cannot fit. Ponatinib's carbon-carbon triple bond linkage is slim enough to pass that obstruction, which made it the only oral option for patients carrying the mutation.

It is used for chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia that is resistant or intolerant to other tyrosine kinase inhibitors, or that carries T315I. Its potency comes at a cost: arterial occlusive events — myocardial infarction, stroke, peripheral arterial disease — occur at rates high enough to carry a boxed warning and are dose-related, which is why current practice starts at a higher dose to achieve response and then reduces. Hepatotoxicity, hypertension, pancreatitis and rash also occur.

Sourcing notes. Originator product, on patent. Four tablet strengths exist specifically to support the response-based dose reduction strategy, so a supply plan needs the range rather than a single strength. Cardiovascular risk assessment at the destination is a practical prerequisite. Oral solid, room temperature.